A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men

Sanoj Punnen, Stephen J. Freedland, Thomas J. Polascik, Stacy Loeb, Michael C. Risk, Stephen Savage, Sharad C. Mathur, Edward Uchio, Yan Dong, Jonathan L. Silberstein

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: The 4Kscore® test accurately detects aggressive prostate cancer and reduces unnecessary biopsies. However, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation. Materials and Methods: Men referred for prostate biopsy at 8 Veterans Affairs medical centers were prospectively enrolled in the study. All men underwent phlebotomy for 4Kscore test assessment prior to prostate biopsy. The primary outcome was the detection of Grade Group 2 or higher cancer on biopsy. We assessed the discrimination, calibration and clinical usefulness of 4Kscore to predict Grade Group 2 or higher prostate cancer and compared it to a base model consisting of age, digital rectal examination and prostate specific antigen. Additionally, we compared test performance in African American and nonAfrican American men. Results: Of the 366 enrolled men 205 (56%) were African American and 131 (36%) had Grade Group 2 or higher prostate cancer. The 4Kscore test showed better discrimination (AUC 0.81 vs 0.74, p <0.01) and higher clinical usefulness on decision curve analysis than the base model. Test prediction closely approximated the observed risk of Grade Group 2 or higher prostate cancer. There was no difference in test performance in African American and nonAfrican American men (0.80 vs 0.84, p = 0.32), The test outperformed the base model in each group. Conclusions: The 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American and nonAfrican American men.

Original languageEnglish (US)
JournalJournal of Urology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Hematologic Tests
African Americans
Prostatic Neoplasms
Biopsy
Prostate
Digital Rectal Examination
Phlebotomy
Decision Support Techniques
Veterans
Prostate-Specific Antigen
Calibration
Area Under Curve
Decision Making

Keywords

  • African Americans
  • biomarkers
  • kallikreins
  • neoplasm grading
  • prostatic neoplasms
  • tumor

ASJC Scopus subject areas

  • Urology

Cite this

A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. / Punnen, Sanoj; Freedland, Stephen J.; Polascik, Thomas J.; Loeb, Stacy; Risk, Michael C.; Savage, Stephen; Mathur, Sharad C.; Uchio, Edward; Dong, Yan; Silberstein, Jonathan L.

In: Journal of Urology, 01.01.2018.

Research output: Contribution to journalArticle

Punnen, Sanoj ; Freedland, Stephen J. ; Polascik, Thomas J. ; Loeb, Stacy ; Risk, Michael C. ; Savage, Stephen ; Mathur, Sharad C. ; Uchio, Edward ; Dong, Yan ; Silberstein, Jonathan L. / A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. In: Journal of Urology. 2018.
@article{b0c254a4abee4adeb6220d50756c2c12,
title = "A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men",
abstract = "Purpose: The 4Kscore{\circledR} test accurately detects aggressive prostate cancer and reduces unnecessary biopsies. However, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation. Materials and Methods: Men referred for prostate biopsy at 8 Veterans Affairs medical centers were prospectively enrolled in the study. All men underwent phlebotomy for 4Kscore test assessment prior to prostate biopsy. The primary outcome was the detection of Grade Group 2 or higher cancer on biopsy. We assessed the discrimination, calibration and clinical usefulness of 4Kscore to predict Grade Group 2 or higher prostate cancer and compared it to a base model consisting of age, digital rectal examination and prostate specific antigen. Additionally, we compared test performance in African American and nonAfrican American men. Results: Of the 366 enrolled men 205 (56{\%}) were African American and 131 (36{\%}) had Grade Group 2 or higher prostate cancer. The 4Kscore test showed better discrimination (AUC 0.81 vs 0.74, p <0.01) and higher clinical usefulness on decision curve analysis than the base model. Test prediction closely approximated the observed risk of Grade Group 2 or higher prostate cancer. There was no difference in test performance in African American and nonAfrican American men (0.80 vs 0.84, p = 0.32), The test outperformed the base model in each group. Conclusions: The 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American and nonAfrican American men.",
keywords = "African Americans, biomarkers, kallikreins, neoplasm grading, prostatic neoplasms, tumor",
author = "Sanoj Punnen and Freedland, {Stephen J.} and Polascik, {Thomas J.} and Stacy Loeb and Risk, {Michael C.} and Stephen Savage and Mathur, {Sharad C.} and Edward Uchio and Yan Dong and Silberstein, {Jonathan L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.juro.2017.11.113",
language = "English (US)",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men

AU - Punnen, Sanoj

AU - Freedland, Stephen J.

AU - Polascik, Thomas J.

AU - Loeb, Stacy

AU - Risk, Michael C.

AU - Savage, Stephen

AU - Mathur, Sharad C.

AU - Uchio, Edward

AU - Dong, Yan

AU - Silberstein, Jonathan L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: The 4Kscore® test accurately detects aggressive prostate cancer and reduces unnecessary biopsies. However, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation. Materials and Methods: Men referred for prostate biopsy at 8 Veterans Affairs medical centers were prospectively enrolled in the study. All men underwent phlebotomy for 4Kscore test assessment prior to prostate biopsy. The primary outcome was the detection of Grade Group 2 or higher cancer on biopsy. We assessed the discrimination, calibration and clinical usefulness of 4Kscore to predict Grade Group 2 or higher prostate cancer and compared it to a base model consisting of age, digital rectal examination and prostate specific antigen. Additionally, we compared test performance in African American and nonAfrican American men. Results: Of the 366 enrolled men 205 (56%) were African American and 131 (36%) had Grade Group 2 or higher prostate cancer. The 4Kscore test showed better discrimination (AUC 0.81 vs 0.74, p <0.01) and higher clinical usefulness on decision curve analysis than the base model. Test prediction closely approximated the observed risk of Grade Group 2 or higher prostate cancer. There was no difference in test performance in African American and nonAfrican American men (0.80 vs 0.84, p = 0.32), The test outperformed the base model in each group. Conclusions: The 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American and nonAfrican American men.

AB - Purpose: The 4Kscore® test accurately detects aggressive prostate cancer and reduces unnecessary biopsies. However, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation. Materials and Methods: Men referred for prostate biopsy at 8 Veterans Affairs medical centers were prospectively enrolled in the study. All men underwent phlebotomy for 4Kscore test assessment prior to prostate biopsy. The primary outcome was the detection of Grade Group 2 or higher cancer on biopsy. We assessed the discrimination, calibration and clinical usefulness of 4Kscore to predict Grade Group 2 or higher prostate cancer and compared it to a base model consisting of age, digital rectal examination and prostate specific antigen. Additionally, we compared test performance in African American and nonAfrican American men. Results: Of the 366 enrolled men 205 (56%) were African American and 131 (36%) had Grade Group 2 or higher prostate cancer. The 4Kscore test showed better discrimination (AUC 0.81 vs 0.74, p <0.01) and higher clinical usefulness on decision curve analysis than the base model. Test prediction closely approximated the observed risk of Grade Group 2 or higher prostate cancer. There was no difference in test performance in African American and nonAfrican American men (0.80 vs 0.84, p = 0.32), The test outperformed the base model in each group. Conclusions: The 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American and nonAfrican American men.

KW - African Americans

KW - biomarkers

KW - kallikreins

KW - neoplasm grading

KW - prostatic neoplasms

KW - tumor

UR - http://www.scopus.com/inward/record.url?scp=85045921236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045921236&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2017.11.113

DO - 10.1016/j.juro.2017.11.113

M3 - Article

AN - SCOPUS:85045921236

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

ER -